IMUX Q3 2024 Earnings — Immunic, Inc. Revenue & Financial Results | Market Cap Arena

IMUXImmunic, Inc.

$135M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$26M

Net Income

-$24M

EPS (Diluted)

$-0.24

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$65M

Total Liabilities

$24M

Stockholders' Equity

$41M

Cash & Equivalents

$59M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$26M	-$24M	-9.1%
Net Income	-$24M	-$23M	-7.0%